Amneal Pharmaceuticals
AMRX
21.12
-0.27
-1.26%
Amneal Pharmaceuticals
US · AMRX
#1854 by market cap
Listed 1970
21.12
-0.27
-1.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $19Market Newswire · 2026/7/22
-
Rating change
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $24Market Newswire · 2026/10/29
-
Rating change
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22Market Newswire · 2026/8/26
-
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/11/4
-
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $24Market Newswire · 2026/10/22
-
Rating change
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy RatingMarket Newswire · 2026/9/21
-
Rating change
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/9/21
-
Rating change
UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy RatingMarket Newswire · 2026/6/12
-
Rating change
Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $19Market Newswire · 2026/7/27
-
Rating change
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $20Market Newswire · 2026/9/17
-
Rating change
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $21Market Newswire · 2026/8/10
-
Leerink Partners Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/11/5
-
Rating change
UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23Market Newswire · 2026/7/15
-
Rating change
Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $21Market Newswire · 2026/7/31
-
UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $28Market Newswire · 2026/11/9
-
Rating change
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $16Market Newswire · 2026/6/11
-
Rating change
Leerink Partners Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23Market Newswire · 2026/9/9
-
Rating change
UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/8/3
-
Rating change
Leerink Partners Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/9/17
-
UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $28Market Newswire · 2026/11/6
-
Rating change
Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $17Market Newswire · 2026/5/26
-
Rating change
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $16Market Newswire · 2026/5/20
-
Rating change
Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/6/4
-
Rating change
Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17Market Newswire · 2026/5/28
-
Rating change
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $17Market Newswire · 2026/4/23
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Amneal Pharmaceuticals discussion 0 comments